

Enabling the Bioeconomy: The Agile BioFoundry

Bioenergy 2016

Blake Simmons

July 13, 2016

The Opportunity Space

The U.S. has ~billion tons of renewable biomass available annually that is a strategic national resource for the bioeconomy



U.S. bioeconomy is estimated at ~\$250B/yr and expected to grow significantly over the next decade



Mobilizing and valorizing this resource through biomanufacturing could rapidly expand the U.S. bioeconomy

Biomanufacturing remains nascent in terms of robustness, scale and standardization

The Challenge: Cost and Time to Market

Molecule	Company	Cost	Time
1,3-Propanediol (PDO) 	DuPont - Tate & Lyle	>\$200M	15 years
Artemisinin 	UC Berkeley, Amyris, Sanofi	>\$150M	10 years

Possible savings of *billions* of dollars by reducing development time of products, reducing energy intensity and increasing carbon efficiency

The Challenge: Engineering Biology is Artisanal




Vision and Mission

Vision: Establish an Agile BioFoundry consortium that will leverage the unique and differentiated capabilities and skills at the labs


Impact: The National Lab consortium, in partnership with academia and industry, aims to achieve:

- 40% decrease in the energy intensity of current manufacturing processes
- 60% decrease in the carbon intensity of current manufacturing processes
- 50% increase in biomanufacturing cycle efficiency (cost, time)
- 10x improvement in Design-Build-Test-Learn cycle efficiency
- New manufacturing technologies, increase US industry competitiveness, and create new opportunities for private sector growth


Agile BioFoundry Enables Sustainable Solutions for Multiple DOE Mission Areas and the Bioeconomy





Breaking the Paradigm: The Agile BioFoundry Approach




Base producer strain



Targets



Scale-Up

1-1000L (ABPDU, NREL)

Predictive toolkits


How Targets will be Identified

Scoring Functions


Pathway Difficulty:
 Gene confidence
 Intermediate toxicity
 Reaction energy
 Pathway length

Resource Usage:
 Synthesis requirements
 Difficulty to test

Value/Benefit:
 Downstream targets
 Economic value
 Institutional value
 GHG Emissions




Multi-objective ranking from selected scoring functions




Reducing Development Costs using Targeted Key Molecules

Retrosynthetic Accessible Chemical Space




- 1 step from host organism
- Selected targets
- Downstream molecules

Example




Proof-of-concept strain engineering success!




(10 downstream molecules)

Agile BioFoundry Approach will Improve Cycle Times and Reduce Costs

1st Generation (Years 1-3)



Program Evolution and State of Operations





Year 3: Assemble and demonstrate distributed Agile BioFoundry capable of simultaneously screening/optimizing 100's of different molecules/pathways in multiple organisms, with key strategic collaborations with industry

Year 5: Demonstrate full operational benefit of the Agile BioFoundry capable of simultaneously screening/optimizing 1000's of different molecules/pathways in multiple organisms relevant to internal and external customers, including industry and other federal agencies

Year 10: Agile BioFoundry Technology fully developed and deployed in the marketplace

Our Vision of the End State

Biological
designs





Scientists &
Engineers


Optimized
organisms &
pathways



BioFoundry



Agile BioFoundry Crosscuts Across DOE and Intersects with Several Federal Agencies



Why DOE? Why Now?

- Unique capabilities that are required to fully realize the entire Design, Build, Test, Learn, Integration, and Scale-up required for the SynBio Foundry
- Grand challenge that brings together multiple DOE programs and capabilities
- Use-inspired, mission driven program that enables achieving goals on renewable energy, biofuels, mission innovation, GHG emission reductions, and marketplace transformation

Systems and Synthetic Biology



High-performance computing



Analytics



Sequencing



Feedstocks



Scale-up



Public Infrastructure Investment Enables Private Industry



Public investment on biomanufacturing infrastructure



Private investment on product development, scaling, and tailoring to unique pathways and products

Adapted from PR campaign of Lyft

Industry Engagement

- **iCORPS seed project completed Q4 FY15**
- **Initiated industry engagement in earnest Q1 FY16**
- **Held two industry listening days on March 15, 2016 in the Bay Area and June 14, 2016 in DC**
 - ❑ **All feedback collected in ThinkTank**
 - ❑ **Intended outcomes**
 - **Overall goal and objectives**
 - **BioFoundry concept**
 - **Management and IP considerations**
 - **Ideal mechanisms for industry collaborations and continued engagement**
 - ❑ **Identify potential members of an Industry Advisory Board to review visioning document**

Industry Interest in the Agile BioFoundry



“I feel like your idea of a biotech foundry could be invaluable to [our company] and I'm looking forward to it.”




“We are very interested in helping build the bio foundry and using it.”




“The bio foundry would be of strategic benefit and help us in terms of open access tools and strain optimization.”



The Agile BioFoundry: Enabling the Bioeconomy



The Agile BioFoundry: Enabling the Bioeconomy



The Impact

- **Distributed, integrated capability operated as a collaboration facility with robust IP management and market transformation approaches**
- **Open approach to sharing data, pathways, organisms, tools, and technologies that enable the bioeconomy and biomanufacturing at the enterprise level**
- **Decrease the energy intensity by at least 40% and carbon intensity by 60%**
- **Increase biomanufacturing cycle efficiency by at least 50%**
- **10x improvement in Design-Build-Test-Learn cycle efficiency**
- **Increase US industry competitiveness, and create new opportunities for private sector growth and jobs**



The Lab Network



**Igor Slowing,
Marit Nilson-Hamilton,
Cynthia Jenks**



**Jennifer Dunn,
Phil Laible,
Felix Odom**



**Dave Thompson,
Erin Searcy, Chenlin
Li,
Rachel Emerson**



**Taraka Dale,
Babs Marrone**



**Jay Keasling, Blake
Simmons, Adam Arkin,
Nathan Hillson, Mary
Maxon, Katy
Christiansen**



**Adam Bratis,
Gregg Beckham,
Mary Bidy,
Eric Payne**



**Tony Palumbo,
Adam Guss,
Brian Davison**



**Malin Young,
Jon Magnuson,
Scott Baker,
Mark Butcher**



**Anup Singh,
John Gladden,
Corey Hudson,
Ryan Davis**

Contact Information



Blake Simmons
basimmons@lbl.gov
415-235-3170

